Insight Molecular Diagnostics Inc (IMDX) Stock Price, Quote & News

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 949 409 7600

Website: imdxinc.com

Address:

2 International Plaza Dr., Suite 510, Nashville, United States

RUNNINWILD Mar. 28 at 11:50 PM

$IMDX STEADY LADS

0 · Reply

JohnPDaly Mar. 27 at 10:01 PM

$IMDX much SP fuckery today but FDA filing is a big deal.

0 · Reply

pThebee Mar. 27 at 5:28 PM

$IMDX feels and smells like a capital raise is coming soon! thats the name of the game

2 · Reply

JohnPDaly Mar. 27 at 5:16 PM

$IMDX We believe that 2026 represents our transition from a product development-stage company into a commercialization-stage company, and accordingly, we are making controlled investments in sales and marketing to support our kidney transplant assay.

0 · Reply

RUNNINWILD Mar. 27 at 4:05 PM

$IMDX opportunity is knocking lads

0 · Reply

JohnPDaly Mar. 27 at 12:26 PM

$IMDX I think I will get a “I Survived the Reverse Split “ hoodie.

0 · Reply

RUNNINWILD Mar. 27 at 6:25 AM

$IMDX

0 · Reply

RBT1369 Mar. 27 at 3:39 AM

$IMDX revenues are coming! While we wait for the FDA: Performing the assay at our lab gives customers an opportunity to get comfortable with the assay as a usual send-out test and should allow for initial incremental revenue. As a reminder, Medicare reimburses GraftAssureCore at a rate of $2,753 per result.

0 · Reply

JohnPDaly Mar. 26 at 9:59 PM

$LCTX spin off $IMDX submitted for FDA approval yesterday. Finish line in sight. Becomes the starting line, but well done.

1 · Reply

JohnPDaly Mar. 26 at 9:45 PM

$IMDX Finish line in sight. Becomes the starting line, but well done.

0 · Reply

Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript

Mar 26, 2026, 4:05 PM EDT - 3 days ago

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Mar 20, 2026, 8:00 AM EDT - 9 days ago

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

Mar 13, 2026, 8:00 AM EDT - 16 days ago

Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score

Mar 3, 2026, 8:00 AM EST - 26 days ago

Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

Feb 11, 2026, 8:00 AM EST - 6 weeks ago

iMDx Announces $26.0 Million Registered Direct Offering

Jan 13, 2026, 9:00 AM EST - 2 months ago

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

Jan 7, 2026, 4:05 PM EST - 2 months ago

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

Jan 6, 2026, 8:00 AM EST - 2 months ago

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Jan 5, 2026, 7:00 AM EST - 2 months ago

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Nov 11, 2025, 7:31 AM EST - 4 months ago

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 4 months ago

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Nov 3, 2025, 4:05 PM EST - 5 months ago

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

Oct 13, 2025, 4:05 PM EDT - 5 months ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Oct 6, 2025, 7:15 AM EDT - 6 months ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Sep 24, 2025, 7:05 AM EDT - 6 months ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 8, 2025, 7:15 AM EDT - 7 months ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:00 AM EDT - 7 months ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Aug 26, 2025, 4:05 PM EDT - 7 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 11, 2025, 4:05 PM EDT - 8 months ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 4, 2025, 4:05 PM EDT - 8 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Jul 30, 2025, 4:05 PM EDT - 8 months ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 28, 2025, 4:05 PM EDT - 8 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jun 23, 2025, 4:05 PM EDT - 9 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 17, 2025, 7:00 AM EDT - 10 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

May 19, 2025, 4:05 PM EDT - 11 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 12, 2025, 11:32 PM EDT - 11 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 11 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

May 7, 2025, 4:10 PM EDT - 11 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Apr 30, 2025, 8:30 AM EDT - 11 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 29, 2025, 8:30 AM EDT - 11 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Mar 24, 2025, 6:53 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 8, 2025, 8:30 AM EST - 1 year ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 6, 2025, 4:05 PM EST - 1 year ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Nov 12, 2024, 8:52 PM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:45 PM EST - 1 year ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 15, 2024, 10:15 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 2 years ago

Oncocyte Reports First Quarter 2024 Financial Results

Apr 12, 2024, 1:44 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 6:00 AM EDT - 2 years ago

Oncocyte Reports Full Year 2023 Financial Results

Apr 9, 2024, 4:05 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

RUNNINWILD Mar. 28 at 11:50 PM

$IMDX STEADY LADS

0 · Reply

JohnPDaly Mar. 27 at 10:01 PM

$IMDX much SP fuckery today but FDA filing is a big deal.

0 · Reply

pThebee Mar. 27 at 5:28 PM

$IMDX feels and smells like a capital raise is coming soon! thats the name of the game

2 · Reply

JohnPDaly Mar. 27 at 5:16 PM

0 · Reply

RUNNINWILD Mar. 27 at 4:05 PM

$IMDX opportunity is knocking lads

0 · Reply

JohnPDaly Mar. 27 at 12:26 PM

$IMDX I think I will get a “I Survived the Reverse Split “ hoodie.

0 · Reply

RUNNINWILD Mar. 27 at 6:25 AM

$IMDX

0 · Reply

RBT1369 Mar. 27 at 3:39 AM

0 · Reply

JohnPDaly Mar. 26 at 9:59 PM

$LCTX spin off $IMDX submitted for FDA approval yesterday. Finish line in sight. Becomes the starting line, but well done.

1 · Reply

JohnPDaly Mar. 26 at 9:45 PM

$IMDX Finish line in sight. Becomes the starting line, but well done.

0 · Reply

StocktwitsEarnings Mar. 26 at 9:32 PM

$IMDX Q4 '25 Earnings Results & Recap Insight Molecular Diagnostics Inc. expects to continue incurring operating losses and negative cash flows in the near future, while investing in R&D for its GraftAssure product offering, aiming to expand beyond kidney transplant rejection testing.

1 · Reply

jackedmund99 Mar. 26 at 8:17 PM

$IMDX $IMDX Only 120 MILLION market cap going after multi billion dollar industry and people are selling it off. How stupid can they be especially in this environment medical Pharma logical healthcare companies are going to do very very well especially ones that cut cost like this company let the idiot sell it. Thank you for the gift under 4

1 · Reply

jackedmund99 Mar. 26 at 8:16 PM

$IMDX start doing the math they’re adressing a $2 billion market if the stock goes to 20 we’re only talking about a $500 million company in a $2 billion marketplace with just one product go ahead and be shortsighted all of you. I’ll stick around.

1 · Reply

AlertsAndNews Mar. 26 at 8:09 PM

$IMDX volume on this IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

0 · Reply

jackedmund99 Mar. 26 at 8:08 PM

$IMDX how stupid did the guy get rid of 10,000 shares on the clothes at $.11 feel right now what a moron this Stock is heading up to double digits in fact in this market healthcare anything related to medicine is gonna go up look at it takeoff goodbye there goes five dollars

0 · Reply

Bogwood Mar. 26 at 8:07 PM

$IMDX Submittal in!!! Lets goo!!!!

0 · Reply

RUNNINWILD Mar. 25 at 7:02 PM

$IMDX hard to get any orders filled at these levels

0 · Reply

NY2CHI Mar. 24 at 7:28 PM

$IMDX added here

0 · Reply

Bogwood Mar. 20 at 5:16 PM

$IMDX I think there's a 25% chance this doesn't drop from a formal submission delay announced next week. Like I've said before, though, if it's truly just the SW, then it'll be an incredible dip to buy, and I predict a huge red-to-green candle move on Friday

1 · Reply

JohnPDaly Mar. 20 at 2:13 PM

$IMDX bought more. ER on the 26th.

0 · Reply

RUNNINWILD Mar. 19 at 5:14 PM

$IMDX "The stock market is a device for transferring money from the impatient to the patient"

0 · Reply

RUNNINWILD Mar. 17 at 4:10 PM

$IMDX continuing to add- remain steadfast lads

0 · Reply

Market Cap	102.04M
Revenue (ttm)	1.88M
Net Income (ttm)	-60.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,226.60%
Debt to Equity Ratio	0.00

Volume	341,800
Avg Vol	93,880
Day's Range	N/A - N/A
Shares Out	28.66M
Stochastic %K	19%
Beta	1.35
Analysts	Sell
Price Target	$8.33